NZ609826A - Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate - Google Patents

Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate

Info

Publication number
NZ609826A
NZ609826A NZ609826A NZ60982611A NZ609826A NZ 609826 A NZ609826 A NZ 609826A NZ 609826 A NZ609826 A NZ 609826A NZ 60982611 A NZ60982611 A NZ 60982611A NZ 609826 A NZ609826 A NZ 609826A
Authority
NZ
New Zealand
Prior art keywords
dimethylamino
propionate
dodecyl
active enantiomer
ddaip
Prior art date
Application number
NZ609826A
Other languages
English (en)
Inventor
Richard Martin
Bassam B Damaj
Original Assignee
Nexmed Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nexmed Holdings Inc filed Critical Nexmed Holdings Inc
Publication of NZ609826A publication Critical patent/NZ609826A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/21Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/221Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ609826A 2010-12-02 2011-11-30 Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate NZ609826A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US41899610P 2010-12-02 2010-12-02
PCT/US2011/062579 WO2012075107A2 (en) 2010-12-02 2011-11-30 Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate

Publications (1)

Publication Number Publication Date
NZ609826A true NZ609826A (en) 2016-03-31

Family

ID=46172526

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ609826A NZ609826A (en) 2010-12-02 2011-11-30 Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate

Country Status (20)

Country Link
US (1) US20130267562A1 (enExample)
EP (1) EP2646015B1 (enExample)
JP (1) JP6109075B2 (enExample)
KR (1) KR102004552B1 (enExample)
CN (1) CN103930105B (enExample)
AU (2) AU2011336692B2 (enExample)
BR (1) BR112013012799A8 (enExample)
CA (1) CA2817417C (enExample)
CL (1) CL2013001391A1 (enExample)
CR (1) CR20130324A (enExample)
ES (1) ES2801999T3 (enExample)
IL (1) IL226173A (enExample)
MX (1) MX2013005522A (enExample)
NZ (1) NZ609826A (enExample)
PH (1) PH12013501104A1 (enExample)
PL (1) PL2646015T3 (enExample)
RU (1) RU2679308C2 (enExample)
SG (2) SG10201803321TA (enExample)
WO (1) WO2012075107A2 (enExample)
ZA (1) ZA201304840B (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014028780A2 (en) * 2012-08-15 2014-02-20 Nexmed Holdings, Inc. Antifungal compounds and methods of use
US8900625B2 (en) 2012-12-15 2014-12-02 Nexmed Holdings, Inc. Antimicrobial compounds and methods of use

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6118020A (en) * 1999-05-19 2000-09-12 Nexmed Holdings, Inc. Crystalline salts of dodecyl 2-(N,N-dimethylamino)-propionate
US6323241B1 (en) * 2000-01-10 2001-11-27 Nexmed (Holdings) Inc. Prostaglandin compositions and methods of treatment for male erectile dysfunction
DE10033853A1 (de) * 2000-07-12 2002-01-31 Hexal Ag Transdermales therapeutisches System mit hochdispersem Siliziumdioxid
JP5160018B2 (ja) * 2002-06-25 2013-03-13 アクルックス・ディ・ディ・エス・プロプライエタリー・リミテッド 非晶質医薬組成物を用いる経皮送達速度調節
US20050181030A1 (en) * 2003-01-03 2005-08-18 Mo Y. J. Topical stabilized prostaglandin E compound dosage forms
EP1635770B1 (en) * 2003-03-21 2009-05-27 Nexmed Holdings, Inc. Antifungal nail coat and method of use
WO2005009510A2 (en) * 2003-07-23 2005-02-03 The Regents Of The University Of California Penetration enhancer combinations for transdermal delivery
PL1670433T3 (pl) * 2003-10-10 2013-03-29 Ferring Bv Przezskórna formulacja farmaceutyczna do zmniejszania pozostałości na skórze
WO2005051960A2 (en) * 2003-11-22 2005-06-09 Midwest Research Laboratories, Llc Hydrocarbyl aminohydrocarbonoates and aminohydrocarbonol hydrocarbonoates as antimicrobial and antiviral agents
RU2012153177A (ru) * 2010-05-04 2014-06-20 Нексмед Холдингс, Инк. Композиции низкомолекулярных терапевтических средств
US8900625B2 (en) * 2012-12-15 2014-12-02 Nexmed Holdings, Inc. Antimicrobial compounds and methods of use

Also Published As

Publication number Publication date
SG10201803321TA (en) 2018-06-28
ES2801999T3 (es) 2021-01-15
BR112013012799A8 (pt) 2018-01-09
CN103930105A (zh) 2014-07-16
AU2011336692B2 (en) 2017-02-16
KR20140023875A (ko) 2014-02-27
AU2017200314A1 (en) 2017-02-02
MX2013005522A (es) 2013-07-17
CA2817417C (en) 2020-12-29
SG190199A1 (en) 2013-06-28
CL2013001391A1 (es) 2013-11-08
US20130267562A1 (en) 2013-10-10
KR102004552B1 (ko) 2019-10-01
PL2646015T3 (pl) 2020-11-30
EP2646015A2 (en) 2013-10-09
RU2679308C2 (ru) 2019-02-07
CR20130324A (es) 2013-08-13
BR112013012799A2 (pt) 2016-09-13
WO2012075107A2 (en) 2012-06-07
CN103930105B (zh) 2019-11-01
WO2012075107A3 (en) 2014-03-06
RU2013119439A (ru) 2015-01-10
JP6109075B2 (ja) 2017-04-05
IL226173A (en) 2016-10-31
JP2014514243A (ja) 2014-06-19
ZA201304840B (en) 2014-04-30
EP2646015A4 (en) 2015-04-08
EP2646015B1 (en) 2020-04-22
AU2011336692A1 (en) 2013-05-30
IL226173A0 (en) 2013-07-31
PH12013501104A1 (en) 2013-07-08
CA2817417A1 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
PH12017501306A1 (en) Inhibitors of histone demethylases
CL2013000399A1 (es) Compuestos derivados de ester de acido boronico; composicion farmaceutica; recipiente esteril; metodo de preparacion; y su uso para el tratamiento o la prevencion de una infeccion bacteriana.
CL2013003372A1 (es) Compuestos derivados de espiro-[1,3]-oxacinas y espiro-[1,4]-oxacepinas, inhibidores de bace1 y/o bace2; composicion farmaceutica; procedimiento para prepararlos; y su uso en el tratamiento y/o la profilaxis de la enfermedad de alzheimer y diabetes.
CL2012003722A1 (es) Compuestos derivados del acido naf-2-ilacetico; composicion farmaceutica; y uso para el tratamiento del sida.
CL2013001316A1 (es) Composicion que comprende micro-organismo probioticos no replicantes que protegen contra las infecciones del tracto respiratorio superior.
CL2014000470A1 (es) Compuestos derivados del acido 2-oxo-piridin-3-carboxilico; composicion farmaceutica; combinacion; y su uso para tratar o mejorar una infeccion bacteriana.
ECSP13012467A (es) Uso de aglutinantes para fabricar formulaciones estables al almacenamiento
GT201200164A (es) "nuevos compuestos de espiropiperidina"
CO6300844A2 (es) Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasa
MX366090B (es) Combinación farmacéutica para usarse en mejorar la tolerancia a la glucosa en pacientes que padecen diabetes de tipo 2.
BR112012032008A2 (pt) anticorpos s100a4 e usos terapêuticos do mesmo
CL2012003523A1 (es) Método para la preparación de una composición farmacéutica que contiene un portador de oxígeno termoestable; composicion farmaceutica que contiene un portador de oxigeno altamente purificado y termoestable.
BRPI1006040A2 (pt) uso de composições farmacêuticas, tipo de curativo médico, e, tipo de caixa de medicamento
IL225438A (en) Use of active pharmacological compounds to treat central nervous system deficiencies
PL2613798T3 (pl) Zastosowanie lizosomalnej kwaśnej lipazy do leczenia niedoboru lizosomalnej kwaśnej lipazy u pacjentów
WO2012106427A3 (en) Methods for treating diabetic foot ulcers
WO2012006149A3 (en) Analogs of c5a and methods of using same
BR112013001539A2 (pt) "dessulfurização oxidativa por meio do uso de um catalisador de titânio (iv) e hidropreróxidos orgânicos"
WO2012003932A3 (en) Use of parvovirus for eliminating cancer stem cells (cscs)
NI201000173A (es) Uso de dronedarona o una sal aceptable farmacéuticamente de ésta, para la preparación de un medicamento para regular el nivel de potasio en la sangre.
CO6460763A2 (es) Métodos y formulaciones ectoparasiticidas
HUE040484T2 (hu) Eljárás (3S,3S')4,4'-diszulfándiilbisz(3-aminobután-1-szulfonsav) elõállítására
MX2011006721A (es) Formulacion farmaceutica de fenofibrato nanonizado.
UA105944C2 (uk) Комбінація теоброміну з деконгестантом і її застосування для лікування кашлю
NZ609826A (en) Active enantiomer of dodecyl 2-(n,n-dimethylamino)-propionate

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 30 NOV 2018 BY SPRUSON + FERGUSON

Effective date: 20160727

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 NOV 2019 BY JAMES + WELLS

Effective date: 20181126

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 NOV 2020 BY IPAN GMBH

Effective date: 20191119

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 30 NOV 2021 BY IPAN GMBH

Effective date: 20201117

LAPS Patent lapsed